1003316-10-6Relevant articles and documents
Design and Synthesis of Novel N-(2-aminophenyl)benzamide Derivatives as Histone Deacetylase Inhibitors and Their Antitumor Activity Study
La, Minh Thanh,Jeong, Byung-Hoon,Kim, Hee-Kwon
, p. 740 - 743 (2021/03/16)
Histone deacetylases (HDACs) are promising therapeutic targets for cancer therapy because inhibition of HDACs triggers growth arrest or apoptosis of tumor cells. In the present study, a new series of fluorinated N-(2-aminophenyl)benzamide derivatives were synthesized to investigate potential inhibition of HDACs and associated anticancer activity. Among the synthesized derivatives, compound 24a showed potent inhibitory activity of HDACs and higher antitumor efficacy in human cancer cell lines (HCT-116, MCF-7, and A549) compared with SAHA. Moreover, animal studies demonstrated that compound 24a showed potent in vivo antitumor efficacy in an HCT-116 colon cancer xenograft mouse model.
SILICON DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS
-
Page/Page column 54-55, (2009/04/25)
The present invention relates to a novel class of Silicon derivatives. The Silicon compounds can be used to treat cancer. The Silicon compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation,
Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2)
Witter, David J.,Harrington, Paul,Wilson, Kevin J.,Chenard, Melissa,Fleming, Judith C.,Haines, Brian,Kral, Astrid M.,Secrist, J. Paul,Miller, Thomas A.
, p. 726 - 731 (2008/12/23)
A class of biaryl benzamides was identified and optimized as selective HDAC1&2 inhibitors (SHI-1:2). These agents exhibit selectivity over class II HDACs 4-7, as well as class I HDACs 3 and 8; providing examples of selective HDAC inhibitors for the HDAC i